布立尼布治疗持续性或复发性宫颈癌的II期评估:NRG肿瘤学/妇科肿瘤学组研究
本研究为II期试验,评估布立尼布治疗持续性或复发性宫颈癌的疗效与耐受性。28例可评估患者中,7例(25%)无进展生存期超过6个月,2例(7%)部分缓解,中位无进展生存期3.2个月,中位总生存期7.9个月;常见3级不良事件包括高血压、贫血等,因药物不可获得试验提前终止。
要点
- 布立尼布800mg每日口服,28天为一周期,用于持续性或复发性宫颈癌。
- 25%患者无进展生存期超过6个月,7%患者部分缓解,中位无进展生存期3.2个月。
- 常见3级不良事件包括高血压、贫血、低钠血症、高血糖、肝酶升高、恶心、头痛和结肠出血。
核心结论
- 基于该II期试验的早期结果,布立尼布耐受性良好,并在第一阶段后显示出足够的活性,但因药物不可获得试验终止。
研究设计与样本
- II期试验,纳入至少接受过一次细胞毒性方案治疗复发且有可测量病灶的持续性或复发性宫颈癌患者,共28例合格且可评估。
主要发现
- 7例(25%)患者无进展生存期超过6个月(90% CI:7.3%-33.9%)。
- 2例(7%)患者部分缓解(90% CI:1.3%-20.8%),缓解持续时间分别为8个月和22个月;12例(43%)疾病稳定。
- 中位无进展生存期为3.2个月(90% CI:2.1-4.4),中位总生存期为7.9个月(90% CI:6.1-11.7)。
- 较常见的3级不良事件包括高血压、贫血、低钠血症、高血糖、肝酶升高、恶心、头痛和结肠出血;4级不良事件包括败血症和高血压。
关键数值与推荐
- 布立尼布800mg每日口服,28天为一周期,直至疾病进展或不可耐受的毒性。
- 主要终点为无进展生存期超过6个月和客观肿瘤缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients. METHODS: Eligible patients had at least one prior cytotoxic regimen for recurrence and with measurable disease. Brivanib 800mg was administered orally every day (1cycle=28days) until disease progression or prohibitive toxicity. Primary endpoints were progression-free survival (PFS) >6months and objective tumor response. RESULTS: Of 28 eligible and evaluable women enrolled, 11 (39%) had primary surgery and 25 (89%) had prior radiation. Eighteen (64%) received one prior cytotoxic treatment and 10 (36%) had 2 prior regimens. Twelve (43%) had >2cycles of brivanib with 4 (14%) receiving >10cycles (range: 1-20). Seven (25%) patients had PFS >6months (90% CI: 7.3%-33.9%). Two (7%) (90% CI: 1.3%-20.8%) patients had partial tumor response with duration of 8 and 22months and 12 (43%) had stable disease. The median PFS was 3.2months (90% CI: 2.1-4.4). The median overall survival was 7.9months (90% CI: 6.1-11.7). More common grade 3 adverse events were hypertension, anemia, hyponatremia, hyperglycemia, elevated liver enzymes, nausea, headache, and colon hemorrhage. Grade 4 adverse events included sepsis and hypertension. CONCLUSIONS: Based on early results of this phase II trial, brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability.
引用
- Chan JK, Deng W, Higgins RV, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017. PMID: 28728751. doi:10.1016/j.ygyno.2017.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。